Notice: This company has been marked as potentially delisted and may not be actively trading. Cleveland BioLabs (CBLI) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrends CBLI vs. ARDS, STAB, NBRV, CMRA, EVLO, AMPE, EFTR, ONCSQ, AEHAW, and MYNZShould you be buying Cleveland BioLabs stock or one of its competitors? The main competitors of Cleveland BioLabs include Aridis Pharmaceuticals (ARDS), Statera Biopharma (STAB), Nabriva Therapeutics (NBRV), Comera Life Sciences (CMRA), Evelo Biosciences (EVLO), Ampio Pharmaceuticals (AMPE), eFFECTOR Therapeutics (EFTR), OncoSec Medical (ONCSQ), Aesther Healthcare Acquisition (AEHAW), and Mainz Biomed (MYNZ). Cleveland BioLabs vs. Aridis Pharmaceuticals Statera Biopharma Nabriva Therapeutics Comera Life Sciences Evelo Biosciences Ampio Pharmaceuticals eFFECTOR Therapeutics OncoSec Medical Aesther Healthcare Acquisition Mainz Biomed Cleveland BioLabs (NASDAQ:CBLI) and Aridis Pharmaceuticals (NASDAQ:ARDS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, community ranking, analyst recommendations, profitability, media sentiment, valuation, institutional ownership, earnings and dividends. Do institutionals and insiders hold more shares of CBLI or ARDS? 5.1% of Cleveland BioLabs shares are owned by institutional investors. Comparatively, 9.7% of Aridis Pharmaceuticals shares are owned by institutional investors. 1.0% of Cleveland BioLabs shares are owned by company insiders. Comparatively, 5.5% of Aridis Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Does the media refer more to CBLI or ARDS? In the previous week, Cleveland BioLabs' average media sentiment score of 0.00 equaled Aridis Pharmaceuticals'average media sentiment score. Company Overall Sentiment Cleveland BioLabs Neutral Aridis Pharmaceuticals Neutral Do analysts prefer CBLI or ARDS? Aridis Pharmaceuticals has a consensus target price of $2.00, indicating a potential upside of 999,900.00%. Given Aridis Pharmaceuticals' higher possible upside, analysts clearly believe Aridis Pharmaceuticals is more favorable than Cleveland BioLabs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Cleveland BioLabs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) N/AAridis Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has more volatility and risk, CBLI or ARDS? Cleveland BioLabs has a beta of 0.7, indicating that its share price is 30% less volatile than the S&P 500. Comparatively, Aridis Pharmaceuticals has a beta of 1.02, indicating that its share price is 2% more volatile than the S&P 500. Is CBLI or ARDS more profitable? Aridis Pharmaceuticals' return on equity of 0.00% beat Cleveland BioLabs' return on equity.Company Net Margins Return on Equity Return on Assets Cleveland BioLabsN/A -32.84% -31.29% Aridis Pharmaceuticals N/A N/A N/A Which has higher valuation and earnings, CBLI or ARDS? Cleveland BioLabs has higher earnings, but lower revenue than Aridis Pharmaceuticals. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCleveland BioLabs$260K0.02-$2.40MN/AN/AAridis Pharmaceuticals$3.09M0.00-$30.37M-$0.160.00 Does the MarketBeat Community favor CBLI or ARDS? Cleveland BioLabs received 154 more outperform votes than Aridis Pharmaceuticals when rated by MarketBeat users. However, 61.00% of users gave Aridis Pharmaceuticals an outperform vote while only 57.50% of users gave Cleveland BioLabs an outperform vote. CompanyUnderperformOutperformCleveland BioLabsOutperform Votes27657.50% Underperform Votes20442.50% Aridis PharmaceuticalsOutperform Votes12261.00% Underperform Votes7839.00% SummaryAridis Pharmaceuticals beats Cleveland BioLabs on 9 of the 12 factors compared between the two stocks. Ad DarwinUnlock the Secret to Earning Consistent Income from Stocks Under $30!Are you ready to transform your investment strategy and generate a steady monthly income? We’re excited to offer you our exclusive report, "Options Trading Strategy: 2 (Surprisingly) Low-Cost Stocks Primed for Generating Monthly Income," FREE!👉 Yes, I Want the Free Report! 👈 Get Cleveland BioLabs News Delivered to You Automatically Sign up to receive the latest news and ratings for CBLI and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip Chart CBLI vs. The Competition Export to ExcelMetricCleveland BioLabsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$5,000.00$6.74B$5.02B$8.40BDividend YieldN/A7.94%7.52%4.16%P/E RatioN/A11.84128.6816.66Price / Sales0.02269.811,718.2576.46Price / CashN/A46.0936.9133.53Price / Book0.005.304.595.18Net Income-$2.40M$150.82M$114.09M$223.67M Cleveland BioLabs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CBLICleveland BioLabsN/A$0.00flatN/AN/A$3,000.00$260,000.000.004Analyst ForecastGap DownARDSAridis Pharmaceuticals0.9009 of 5 stars$0.00flat$2.00+999,900.0%-99.8%$11,000.00$3.09M0.0030Gap DownSTABStatera BiopharmaN/A$0.00flatN/AN/A$11,000.00$1.49M0.0020Gap DownNBRVNabriva TherapeuticsN/A$0.00flatN/A+173.2%$10,000.00$35.59M0.0039Analyst ForecastNews CoverageCMRAComera Life SciencesN/A$0.00flatN/A-100.0%$6,000.00$1.00M0.002EVLOEvelo BiosciencesN/A$0.00flatN/A-99.9%$4,000.00N/A0.00120AMPEAmpio PharmaceuticalsN/A$0.00flatN/A-99.9%$2,000.00N/A0.0020EFTReFFECTOR TherapeuticsN/A$0.00flat$24.00+5,999,900.0%-100.0%$2,000.00$3.55M0.0010Gap DownONCSQOncoSec MedicalN/AN/AN/AN/A$1,000.00N/A0.0040AEHAWAesther Healthcare AcquisitionN/A$0.04flatN/A+219.2%$0.00N/A0.002MYNZMainz Biomed2.1336 of 5 stars$0.26-7.3%$3.00+1,076.5%-90.2%$0.00$900,000.00-0.1630Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Aridis Pharmaceuticals Alternatives Statera Biopharma Alternatives Nabriva Therapeutics Alternatives Comera Life Sciences Alternatives Evelo Biosciences Alternatives Ampio Pharmaceuticals Alternatives eFFECTOR Therapeutics Alternatives OncoSec Medical Alternatives Aesther Healthcare Acquisition Alternatives Mainz Biomed Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CBLI) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”Tim Sykes - the world’s most apolitical Millionaire trader - just sat down for an urgent election interview… ...Timothy Sykes | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cleveland BioLabs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cleveland BioLabs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
